| A non-apoptotic role for caspase-9 in muscle differentiation TVA Murray, JM McMahon, BA Howley, A Stanley, T Ritter, A Mohr, ... Journal of cell science 121 (22), 3786-3793, 2008 | 184 | 2008 |
| Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model A Mohr, M Lyons, L Deedigan, T Harte, G Shaw, L Howard, F Barry, ... Journal of cellular and molecular medicine 12 (6b), 2628-2643, 2008 | 140 | 2008 |
| Manganese superoxide dismutase induces p53-dependent senescence in colorectal cancer cells L Behrend, A Mohr, T Dick, RM Zwacka Molecular and cellular biology 25 (17), 7758-7769, 2005 | 129 | 2005 |
| Histone deacetylase inhibitors cooperate with IFN-γ to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8 S Häcker, A Dittrich, A Mohr, T Schweitzer, S Rutkowski, J Krauss, ... Oncogene 28 (35), 3097-3110, 2009 | 124 | 2009 |
| The future of mesenchymal stem cell-based therapeutic approaches for cancer–from cells to ghosts A Mohr, R Zwacka Cancer letters 414, 239-249, 2018 | 121 | 2018 |
| Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells A Mohr, SM Albarenque, L Deedigan, R Yu, M Reidy, S Fulda, ... Stem cells 28 (11), 2109-2120, 2010 | 121 | 2010 |
| Constitutively activated nuclear factor-κB, but not induced NF-κB, leads to TRAIL resistance by up-regulation of X-linked inhibitor of apoptosis protein in human cancer cells SJ Braeuer, C Büneker, A Mohr, RM Zwacka Molecular cancer research 4 (10), 715-728, 2006 | 110 | 2006 |
| TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors D Stadel, A Mohr, C Ref, M MacFarlane, S Zhou, R Humphreys, ... Clinical cancer research 16 (23), 5734-5749, 2010 | 99 | 2010 |
| Both human and mouse mesenchymal stem cells promote breast cancer metastasis SM Albarenque, RM Zwacka, A Mohr Stem cell research 7 (2), 163-171, 2011 | 84 | 2011 |
| Caspase-8L expression protects CD34+ hematopoietic progenitor cells and leukemic cells from CD95-mediated apoptosis A Mohr, RM Zwacka, G Jarmy, C Büneker, H Schrezenmeier, K Döhner, ... Oncogene 24 (14), 2421-2429, 2005 | 81 | 2005 |
| The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells DA Leach, A Mohr, ES Giotis, E Cil, AM Isac, LL Yates, WS Barclay, ... Nature Communications 12 (1), 4068, 2021 | 71 | 2021 |
| Src homology 2-containing inositol 5-phosphatase 1 binds to the multifunctional docking site of c-Met and potentiates hepatocyte growth factor-induced branching tubulogenesis M Stefan, A Koch, A Mancini, A Mohr, KM Weidner, H Niemann, T Tamura Journal of Biological Chemistry 276 (5), 3017-3023, 2001 | 67 | 2001 |
| AAV-encoded expression of TRAIL in experimental human colorectal cancer leads to tumor regression A Mohr, G Henderson, L Dudus, I Herr, T Kuerschner, KM Debatin, ... Gene therapy 11 (6), 534-543, 2004 | 60 | 2004 |
| MnSOD protects colorectal cancer cells from TRAIL-induced apoptosis by inhibition of Smac/DIABLO release A Mohr, C Büneker, RP Gough, RM Zwacka Oncogene 27 (6), 763-774, 2008 | 59 | 2008 |
| Apoptosis induction in peripheral leukemia cells by remission induction treatment in vivo: selective depletion and apoptosis in a CD34+ subpopulation of leukemia cells K Stahnke, S Eckhoff, A Mohr, LH Meyer, KM Debatin Leukemia 17 (11), 2130-2139, 2003 | 59 | 2003 |
| Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects R Yu, L Deedigan, SM Albarenque, A Mohr, RM Zwacka Cell death & disease 4 (2), e503-e503, 2013 | 53 | 2013 |
| DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer R Yu, SM Albarenque, RH Cool, WJ Quax, A Mohr, RM Zwacka Cancer biology & therapy 15 (12), 1658-1666, 2014 | 44 | 2014 |
| Identification of deficient mitochondrial signaling in apoptosis resistant leukemia cells by flow cytometric analysis of intracellular cytochrome c, caspase-3 and … K Stahnke, A Mohr, J Liu, LH Meyer, L Karawajew, KM Debatin Apoptosis 9, 457-465, 2004 | 41 | 2004 |
| The TRAIL-receptor-1: TRAIL-receptor-3 and-4 ratio is a predictor for TRAIL sensitivity of cancer cells C Bueneker, A Mohr, RM Zwacka Oncology reports 21 (5), 1289-1295, 2009 | 32 | 2009 |
| A novel method for the combined flow cytometric analysis of cell cycle and cytochrome c release A Mohr, RM Zwacka, KM Debatin, K Stahnke Cell Death & Differentiation 11 (10), 1153-1154, 2004 | 29 | 2004 |
